New FDA Guidance on Psychedelics Research Helps Set Legal Framework for Nascent Field
Healthcare & Life Sciences Team co-leader Michael Werner was quoted in a Corporate Counsel article discussing the landscape of psychedelic drugs in clinical trials. Psychedelics research is increasing amid optimism that the drugs effectively treat numerous conditions, from depression to addiction. Mr. Werner highlights potential challenges in navigating DEA regulations, emphasizing the importance of moving forward considerately and responsibly.
"You're talking about using a drug substance that previously the government said has no medical purpose. They [agencies] want it to go forward in a very controlled way. What they don't want to have is people doing it in their garage," he said.